The Federal Schedule III Order Has Significant Implications for Washington’s Cannabis Policy
A few weeks after the Schedule III announcement, one thing is clear: for Washington, there are no simple answers.
On April 23, 2026, the U.S. Department of Justice issued a Final Order moving two categories of marijuana from Schedule I to Schedule III under the Controlled Substances Act: FDA-approved marijuana drug products, and marijuana covered by a state medical marijuana license. Adult-use cannabis remains in Schedule I. A separate federal hearing process will consider broader rescheduling beginning June 29.
A note on terminology: federal law uses "marijuana," while Washington State uses "cannabis." The terms generally refer to the same substance but reflect different legal frameworks and evolving policy language.
The order creates a limited pathway for federal recognition of certain state-licensed medical cannabis activity. For qualifying businesses, it may unlock relief from Section 280E, which has long prevented cannabis operators from taking standard federal business deductions. Longstanding barriers to meaningful, broad research have also been substantially reduced.
In the order, the DEA outlines a 60-day window for state medical licensees to apply for Schedule III registration. It states that, to facilitate a prompt transition, applications submitted within that window will be processed within six months, and early applicants may continue operating under their state-issued licenses while their applications are under review. What happens after that 60 day window is unclear.
The broader system remains unchanged. Federal criminalization still exists. Adult-use cannabis remains Schedule I, and state-regulated systems continue to operate in tension with federal law. Most practical details remain unclear, including how businesses qualify, how operations must be structured, and how compliance will be evaluated. Washington faces a uniquely complex path to align with the new order.
Washington's Structure Complicates the Opportunity
Washington is not starting from a blank slate. In 2015, with the passage of SB 5052, the Cannabis Patient Protection Act, the Washington State Legislature folded the medical market into the adult-use I-502 system. That transition led to the closure of many legacy medical operators who did not enter the new system, and a number of patients left the regulated market. The result was a largely integrated commercial framework rather than a clearly distinct medical system. That integrated structure now creates real challenges for participation in the emerging federal Schedule III pathway. Most cannabis businesses in Washington serve both adult-use consumers and medical patients under a single license with a medical endorsement.
The order makes clear that federal regulators are prepared to give weight to state systems, but only under specific conditions. It states, “In general, registration of an applicant that complies with a state-law regime that contains robust protections against diversion, requirements for record-keeping and reporting, and safety and inspection measures will not be inconsistent with the public interest so long as registration is consistent with the Single Convention.”
The order does not explicitly prohibit a business from engaging in both Schedule I and Schedule III activity, but it creates a framework where doing so is likely untenable. Schedule III participation requires DEA registration and full compliance with federal law, while most existing cannabis activity in Washington remains Schedule I and federally prohibited. In practice, this pushes Washington businesses toward a difficult choice about which side of the federal framework they operate within. Without clear guidance from the state, efforts to navigate both pathways carry legal and operational risk.
Patients and Equity Are at Risk of Being Left Behind
Washington’s medical cannabis system has always mattered, even as policy conversations have shifted toward the adult-use market. Patients rely on consistent access to appropriate products, affordability, higher possession limits, and informed retail support. That reality has not changed.
Moments like this tend to reward those with capital, legal resources, and administrative capacity. Without deliberate action, early advantages will concentrate among the most well-positioned operators.
Social Equity Applicants face particular risk. Many are still navigating licensing delays, financing constraints, and administrative barriers. A compressed federal window could pass before they are in a position to participate.
What Washington Should Do Now
Washington does not have the luxury of waiting for perfect clarity. The federal window is already open, and the structure of Washington’s system leaves businesses with limited time to evaluate difficult choices. Longer-term modernization can and should happen in the next legislative session, but that does not solve the immediate problem. The priority now is establishing a workable bridge that allows businesses to understand their options and act within the federal timeline.
Practical interim steps include:
Coordination between the Washington State Liquor and Cannabis Board, Department of Health, and Attorney General's Office to provide guidance on how existing medical endorsements and patient-facing operations may align with federal definitions
Leadership from the Governor’s Office to apply pressure at the federal level for greater clarity regarding the 60-day window, including evaluation criteria and transparency into what follows that period
Focused attention on ensuring Social Equity Applicants are not excluded from early opportunities
Washington has an opportunity to act quickly and preserve as many options as possible for patients, small businesses, and emerging operators. Without that action, the advantages of early participation will accrue to states that move faster.
What Can You Do Now
This moment is moving faster than most policy processes, and many of the people responsible for shaping Washington’s response are still getting up to speed. That creates both risk and opportunity.
First, contact your legislators, agency leaders, and policy staff. Do not assume they are tracking the details of the federal change or understand how it interacts with Washington’s system. Most do not. Clear, direct outreach from constituents and stakeholders can help ensure this issue is treated with the urgency it requires and that early decisions are informed by real operational and patient impacts.
Second, engage directly with the policymaking process. Apply to testify at the June 29 federal hearing and encourage others to do the same. This process will help shape how the rule is implemented, and Washington needs to be represented. The perspectives of patients, small businesses, and Social Equity Applicants are especially important at this stage.
Early engagement matters. The decisions made in the coming weeks will shape who is able to participate and who is left behind.